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Summary 
How we measure excretory renal function is a core component of clinical nephrology 
encountered daily in clinics around the world, but there is still uncertainty about the 
optimal measurement for patients with advanced kidney disease (when eGFR 
prediction equations are less reliable). This cohort study from the Swedish CKD 
Registry compares routinely collected plasma-iohexol measured GFR or 24-hr urine 
clearances with eGFR to predict mortality in a large number of Swedish patients with 
Stage 4/5 CKD. We found that mGFR has a statistically superior performance to eGFR 
in both aetiological and prognostic models, demonstrating the importance of GFR per 
se versus non-GFR determinants of outcome. However, the relatively modest 
enhancement suggests that eGFR may be sufficient to use in everyday clinical practice 
while mGFR adds important prognostic information for those where eGFR is believed to 
be biased.  
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Abstract 
Background 
Estimated GFR (eGFR) becomes less reliable in patients with advanced chronic kidney 
disease (CKD).  
Methods 
Using the Swedish CKD Registry (2005-2011), linked to the national inpatient, dialysis and 
death registers, we compared the performance of plasma-iohexol measured GFR (mGFR) 
and urinary clearance measures versus eGFR to predict death in adults with CKD Stages 4/5. 
Performance was assessed using survival, and prognostic models. 
Results 
Of 2705 patients, 1517 had mGFR performed, with the remainder providing 24-hr urine 
clearances. Median eGFR (CKD-EPIcreatinine) was 20ml/min/1.73m2 (interquartile range 
[IQR] 14–26), mGFR 18ml/min/1.73m2 (IQR 13–23) and creatinine clearance 23ml/min 
(IQR 15-31). Median follow-up was 45 months (IQR 26-59), registering 968 deaths 
(36%). In fully-adjusted Cox models, a rise in mGFR of 1ml/min/1.73m2 was associated 
with a 5.3% fall in all-cause mortality compared with a 1.7% corresponding fall for eGFR 
(adjusted hazard ratio [aHR] 0.947 [95%CI 0.930–0.964] versus aHR 0.983 [95%CI 
0.970–0.996]). mGFR was also statistically superior in prognostic models 
(discrimination using logistic regression and integrated discrimination improvement). 
Urinary clearance measures showed a stronger aetiological relationship with death than 
eGFR but were not statistically superior in the prognostic models.  
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Conclusions 
The performance of mGFR was superior to eGFR, in both aetiological and prognostic 
models, in predicting mortality in adults with CKD stage 4/5, demonstrating the 
importance of GFR per se versus non-GFR determinants of outcome. However, the 
relatively modest enhancement suggests that eGFR may be sufficient to use in 
everyday clinical practice while mGFR adds important prognostic information for those 
where eGFR is believed to be biased.  
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Introduction 
Chronic kidney disease (CKD) is associated with adverse patient outcomes(1). 
Identifying reduced glomerular filtration rate (GFR) is key for the classification of kidney 
disease and prognostication for patients with CKD(2). GFR is approximated by 
measuring plasma clearance of an exogenous substance such as iohexol (measured 
GFR [mGFR]) or measuring an endogenous marker, such as creatinine. Estimated 
GFR (eGFR) is derived from the serum creatinine concentration, adjusted for creatinine 
generation on the basis of age, sex and race. Urinary creatinine excretion can be 
measured directly using a timed urine collection (usually 24 hours) and calculating the 
creatinine clearance (Creat-Cl)(3).  
Creatinine based eGFR is subject to inaccuracy; eGFR over-estimates true GFR in 
people with low muscle mass (reduced creatinine generation), including those with 
advanced kidney or liver disease(4-6) and underestimates GFR in case of high muscle 
mass. However urinary creatinine excretion, which is a measure for muscle mass, is 
also an independent prognostic marker; low creatinine excretion is associated with 
increased all-cause mortality(7). These associated observations affect the utility of 
creatinine based eGFR both as a measure of excretory kidney function (due to 
inaccuracy), and as a prognostic marker for increased mortality. This is because the 
relationship between eGFR and adverse outcomes is confounded by creatinine 
generation. Creatinine generation is a key non-GFR determinant of outcome. Whether 
accurate measure of kidney function or prognostic ability should take precedence in our 
choice of filtration marker is debated(8, 9). 
In Sweden, many patients with advanced CKD routinely have formal GFR 
measurement (mGFR or urinary urea/creatinine clearance) along with eGFR. To assess 
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the contribution of GFR and non-GFR determinants to patient outcome, we compared 
the performance of eGFR with measured GFR to predict all-cause mortality in patients 
registered with the Swedish Renal Registry – Chronic Kidney Disease (SRR-CKD).  
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Subjects and Methods 
Study population 
SRR-CKD prospectively collects data for all patients attending 49 of 51 nephrology 
clinics in Sweden (2014) with incident eGFR<45ml/min/1.73m2(10). GFR 
measurements (iohexol mGFR or urinary clearances of urea, creatinine or urea-
creatinine) are performed routinely in most Swedish nephrology clinics, but there is no 
uniform protocol. This study included patients ≥18 years who had either an iohexol 
mGFR and/or urinary clearance (creatinine clearance [Creat-Cl], urea clearance [Urea-
Cl] or urea-creatinine clearance [Urea-Creat-Cl]) and a serum creatinine measurement 
between 1st January 2005 and 31st December 2011, on the day of a nephrology clinic 
visit (for contemporaneous clinical measures). Data linkage with the Swedish Inpatient 
Register provided co-morbidity data (ICD-10 codes from 1987 onwards), to calculate 
Charlson scores(11). We linked with the SRR and the Cause of Death Registry for date 
of renal replacement therapy (RRT) (including pre-emptive transplantation) and vital 
status until 30th Sept 2013. Duplicates were removed, then patients were excluded 
(criteria shown in Figure 1). Outlier GFR results were removed on the assumption that 
the result was not biologically plausible (when the absolute difference between mGFR 
and eGFR was >3 standard deviations from the mean absolute population difference). 
Primary renal diagnosis (PRD) was reported according to the European Renal 
Association codes(12). 
Laboratory measurements 
Iohexol is an iodinated contrast agent excreted via glomerular filtration; its elimination 
from plasma is used as an indirect measure of GFR. Iohexol plasma clearance is 
performed by injecting 2-10mls of iohexol intravenously. After 6-24 hours (depending on 
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the estimated GFR) a blood sample is drawn and iohexol concentration is measured 
using high performance liquid chromatography (HPLC). mGFR is then calculated using 
a formula based on the individual’s age, sex and distribution volume. It performs well in 
comparison with inulin clearance(13). The iohexol mGFR protocols used in Swedish 
clinics differ only slightly and the national quality assurance programme was operating 
during the study period(14). A description of iohexol plasma clearance calculation is 
given in supplementary material. 
Swedish laboratories analysed serum creatinine using an enzymatic method or 
corrected Jaffe method, which are isotope dilution mass spectrometry traceable. 
Performance as assessed by the Swedish Clinical Chemistry Association was 
acceptable(15). eGFR was calculated using the CKD-EPIcreatinine formulae(16). 
Urinary urea and creatinine measurements were reported using the absolute value 
(ml/min) while mGFR and eGFR were reported with a correction for body surface area 
(BSA) of 1.73m2, reflecting routine clinical care. However for the analyses, the urinary 
clearance measures were corrected for BSA of 1.73m2 to allow a fair comparison with 
mGFR/eGFR. 
 
Statistical analysis 
Statistical analyses were undertaken using SPSS for Mac version 21 (IBM). Descriptive 
statistics are presented as mean ± standard deviation or median (interquartile range). 
Between group differences were assessed according to the data distribution. Multiple 
imputation was performed for variables when <10% data missing, with 20 imputations, 
and pooled results used, unless otherwise specified. 
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The cohort was divided into tertiles according to the clearance marker (ie tertiles of 
iohexol mGFR, eGFR, Creat-Cl [all adjusted for BSA of 1.73m2]), and Kaplan Meier 
unadjusted survival plots were constructed comparing outcome for the clearance 
markers, by tertile. Cox proportional hazard survival models were constructed for all-
cause mortality. Potential confounders were identified from direct acyclic graphs (DAG; 
dagitty.net) and the assumptions of conditional independence in the DAG were 
confirmed using linear regression. Co-variates were included in order to assess the 
effects of the predictor on mortality. The DAG used to produce the models is provided in 
the Supplementary material (Figure S1). The proportional hazards assumption was 
tested for each continuous variable by plotting Schoenfeld residuals against time, using 
loess smoothing. Log minus log plots were used for categorical variables. The 
proportional hazards assumption was tested by creating time-dependant co-variates for 
each variable, assessing for interaction and were included in the model as a time-
dependant co-variate if the interaction was significant.  
Model 1 included age and gender as co-variates. Model 2 (see DAG in Figure S1) was 
adjusted for: age, gender, Charlson Score, PRD, body mass index (BMI) and serum 
albumin. Model 3 (see DAG in Figure S1), included Model 2 co-variates plus pulse 
pressure, haemoglobin and commencement of RRT (time-varying co-variate). Each of 
the predictors was added to the model in turn; iohexol mGFR, eGFR, Creat-Cl, Urea-Cl, 
Urea-Creat-Cl (all adjusted for BSA of 1.73m2). The adjusted hazard ratios (aHR) 
presented are for a one-unit rise in the predictor variable. However Creat-Cl is generally 
higher than eGFR and Urea-Cl is generally lower, introducing potential bias. Therefore 
sensitivity analyses were performed; each predictor was log-transformed (not normally 
distributed) and then standardised for fair comparison. For these analyses, the hazard 
ratios are per one standard deviation on a logarithmic scale. eGFR CKD-EPIcreat was 
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used since it is recommended by KDIGO and performed well in comparison to iohexol 
mGFR in a cross-sectional analysis of the SRR-CKD(2, 4). Sensitivity analyses were 
also performed comparing the performance of the urinary clearance markers without 
correction for BSA. 
Several methods are used to estimate the predictive performance of a model. The 
diagnostic performance is studied through discrimination, separating those diagnosed 
with the event from those not experiencing it. In this context, good discrimination means 
that low GFR always produce higher predicted risk than high GFR. In our study, model 
discrimination was assessed using C-statistics derived by two methods. Multivariate 
logistic regression models for 2-yr all-cause mortality were built using each predictor in 
turn with the covariates from the Cox model 3 (using data from the 20th imputation). The 
C-statistics were calculated by constructing Receiver Operator Characteristic (ROC) 
curves using the predicted probability from the logistic regression model. Differences 
between the area under the curve (AUC) of ROC curves was assessed using Hanley 
and McNeill’s method(17). In addition, Harrell’s C was calculated for each clearance 
measure using the output from the adjusted Cox survival model, utilising the total 
follow-up time available (using Model 3 and data from 20th imputation)(18). These 
models were built in order to compare the performance of the different measures of 
renal function, and not for clinical use as a predictor of prognosis. 
Calibration assesses the agreement between the observed and the predicted risk by 
the model. Calibration was assessed using the Hosmer-Lemeshow test; a non-
significant p value suggests model calibration (ie no significant difference in proportion 
of participants predicted versus observed to die). Integrated Discrimination 
Improvement (IDI) compared the performance of mGFR or urinary clearance measures 
versus eGFR (as reference) to predict all-cause mortality. The same multivariate model 
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was used as for discrimination. IDI measures the proportion correctly re-classified to a 
higher or lower risk with the addition of the new biomarker. It is superior to net 
reclassification index as it incorporates direction and magnitude of risk reclassification, 
and does not rely on a selected threshold(19).  
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Results 
The cohort included 2,705 patients, 1517 with an iohexol mGFR and eGFR performed 
contemporaneously and 1,188 with a urinary clearance and eGFR measured 
contemporaneously; see the flowchart of population and exclusions (Figure 1).  
Background data are shown in Table 1, except data regarding race (illegal to record in 
Sweden). Patients were followed for a median of 45 months (interquartile range [IQR] 
26-59).  
Scatterplots demonstrating the relationship between the measures of GFR are shown in 
Supplementary Figure S2.  
Outcomes 
There were 968 deaths during follow-up (35.8% of the total cohort). For those who died 
during follow-up, median time to death from baseline was 23 months (IQR 11–39). RRT 
was commenced in 1087 patients (40.2%). There were 621 deaths (23.0%) without 
starting RRT and 347 patients (12.8%) died after starting RRT. Subsequent mortality 
analyses include all deaths (with or without RRT initiation). See Figure 1 for details of 
the mGFR and urinary clearance subgroups. 
Aetiological models 
mGFR versus eGFR to predict mortality 
Kaplan Meier plots of unadjusted survival, comparing tertiles of clearance marker are 
shown in Figure 2. Cox regression analyses comparing iohexol mGFR and eGFR as 
predictors of all-cause mortality are shown in Table 2 and Figure 3 (unadjusted model) 
and Supplementary Figure S3 (adjusted model). Given the inverse relationship between 
GFR and survival, a lower aHR is suggestive of a stronger relationship between the 
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measure of GFR and all-cause mortality. In the fully adjusted model (Model 3 in Table 
2) a rise in mGFR of 1ml/min/1.73m2 was associated with a 5.3% lower all-cause 
mortality compared with 1.7% lower for the corresponding change in eGFR (aHR 0.947 
[95%CI 0.930–0.964] versus aHR 0.983 [95%CI 0.970–0.996]). In the sensitivity 
analyses, the relationship is maintained with a 1-SD rise in mGFR (on a logarithmic 
scale) being associated with a 29.1% lower mortality (aHR 0.701 [95%CI 0.633–0.793]) 
versus only 8.7% lower for eGFR (aHR 0.913 [95%CI 0.821–1.016]).  
Urinary clearance versus eGFR to predict mortality 
Cox regression analyses comparing urinary clearance measures and eGFR as 
predictors of all-cause mortality were performed. Multiple measures of urinary clearance 
were available in different sub-groups (see Figure 1). Multiple comparisons were only 
made when all measures were available contemporaneously in a sub-group. 
Creat-Cl was measured in 1076 participants and the comparison with eGFR is shown in 
Table 3, Figures 2&3 (unadjusted model) and Supplementary Figure S3 (adjusted 
model). Urea-Creat-Cl was measured in 527 participants and the comparisons with 
Creat-Cl, Urea-Cl and eGFR are shown in Table 4, Figures 2&3 (unadjusted model) 
and Supplementary Figure S3 (adjusted model).  
Urinary Creat-Cl vs eGFR 
In the fully adjusted Cox model (Model 3, Table 3), a rise in Creat-Cl of 1ml/min (per 
1.73m2) was associated with 2.3% lower all-cause mortality compared with 1.7% lower 
for the corresponding change in eGFR (per 1.73m2) (aHR 0.977 [95%CI 0.967–0.988] 
versus aHR 0.983 [95%CI 0.969–0.998]). In the sensitivity analyses, the relationship 
between the performances of the filtration markers change; a 1-SD rise in Creat-Cl (on 
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a logarithmic scale) was associated with 23.9% lower mortality (aHR 0.761 [95%CI 
0.686–0.846]) versus only 9.3% lower for eGFR (aHR 0.907, [95%CI 0.812–1.013]).   
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Urinary Urea-Cl 
For Urea-Cl versus eGFR the mortality is 4.6% versus 0.9% lower (aHR 0.954 [0.931–
0.978] and 0.991 [0.971–1.011] respectively) in the fully-adjusted model (Model 3, 
Table 4). In the sensitivity analyses, a markedly altered relationship is observed, with a 
1-SD rise in Urea-Cl (logarithmic scale) associated with 29.1% lower mortality versus 
3.1% (aHR 0.709 [0.607–0.829] and 0.969 [0.833–1.128] respectively), in the fully 
adjusted model.  
Urinary Urea-Creat-Cl 
For Urea-Creat-Cl versus eGFR, mortality was 3.1% versus 0.9% lower (aHR 0.969 
[0.950–0.988] and 0.991 [0.971–1.011] respectively) in the fully-adjusted model (Model 
3, Table 4). In the sensitivity analyses, an altered relationship is again observed, with a 
1-SD rise in Urea-Creat-Cl (on a logarithmic scale) associated with 25.5% lower 
mortality versus 3.1% (aHR 0.745 [0.639–0.868] and 0.969 [0.833–1.128] respectively), 
again when the model was fully adjusted for co-variates.  
Therefore, within the sub-group with multiple urine clearance measures, the Urea-Cl 
had the strongest relationship with all-cause mortality. Sensitivity analyses were also 
performed for the urinary clearance markers without adjustment for BSA, (shown in 
Supplementary Tables S1 and S2) and the relative performance of the clearance 
markers was unchanged.  
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Prognostic Models 
Discrimination and Calibration 
Model discrimination for mGFR, Creat-Cl and Urea-Creat-Cl, compared to eGFR are 
shown in Figure 4 (and supplementary Table S3). The C-statistic (from the 2-yr logistic 
regression model) was significantly higher for mGFR than eGFR demonstrating 
superior discrimination, using Hanley and McNeill’s method of comparing the AUC of 
ROC curves.(17) The parameter estimates for variables in the logistic regression 
models are shown in Table S4. In the urinary clearance groups the differences were not 
significant. Using Harrell’s C, the relative discriminative performance of the clearance 
measures was the same as the logistic regression method, except for mGFR and eGFR 
where no clear difference was seen between the two measures. All the models were 
well calibrated using Hosmer-Lemeshow goodness of fit test (no significant differences 
between the expected and observed proportion who died) (supplementary Table S3). 
Integrated Discrimination Improvement 
IDI was used to assess improvement in the prognostic model with mGFR or urinary 
clearance measures in place of eGFR. The results are shown in supplementary Table 
S4. Replacing eGFR with mGFR resulted in a improvement in the IDI (overall IDI 
0.023). However, replacement of eGFR with Creat-Cl, Urea-Cl or Urea-Creat-Cl did not 
result in a significant change in the IDI.   
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Discussion 
We have shown that mGFR (iohexol plasma clearance) is a superior predictor of all-
cause mortality than eGFR in a Swedish Registry population of patients with CKD. 
However the demonstration of a stronger relationship does not necessarily mean that 
the predictor has a superior influence on prognosis. Therefore both aetiological models 
(to demonstrate the strength of the relationship) and prognostic models (to compare the 
contribution of the respective markers to prognostication) are needed, as performed 
here. In our models we show that the measured GFR is consistently superior across the 
aetiological Cox models (adjusted and unadjusted), demonstrating the importance of 
GFR itself as a predictor of adverse outcome over the additional non-GFR determinants 
of outcome associated with creatinine-derived eGFR. Prognostic models were built to 
allow comparison of the performance of the markers, and have not been validated for 
clinical use to estimate prognosis. Measured GFR was also generally superior to eGFR 
in the prognostic models (discrimination using 2-yr logistic regression model, calibration 
and IDI, but discriminative performance of mGFR and eGFR was similar using Harrell’s 
C).  
However, the relative performance of mGFR in the prognostic models was weaker than 
the aetiological models. Creatinine-based eGFR using the CKD-EPI formulae 
performed well in the prognostic model, and while mGFR was superior, the difference 
was modest (at best) and may not be clinically relevant.  
In a separate sub-group, urinary clearance measures were performed. There were 
significant differences in the baseline characteristics between the iohexol mGFR group 
and the urinary clearance group therefore direct comparisons between mGFR and 
urinary clearance cannot be made. However comparisons can be made between 
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different urinary clearance measures performed in the same patients. Supplementary 
Figure S2 demonstrates the relationship between Creat-Cl, Urea-Cl and combined 
Urea-Creat-Cl versus eGFR respectively in the cohort. Creat-Cl is generally higher than 
eGFR for a given patient due to a relative increase in tubular secretion of creatinine in 
advanced CKD (median Cr Cl 23ml/min), Urea-Cl is lower due to tubular re-absorption 
(median Ur Cl 14ml/min), and the combined Urea-Creat-Cl is closest to eGFR in the 
cohort (18ml/min and 20ml/min/1.73m2 respectively). Urinary clearance measures 
showed less consistent performance than mGFR across the aetiological and prognostic 
models. Given the systematic differences in measurement of the filtration markers 
observed above, (e.g. Creat-Cl being consistently higher than Urea-Cl at a given level), 
the sensitivity analyses aided interpretation (using log transformation and 
standardisation to remove these differences). Each urinary filtration marker showed a 
strong independent relationship with all-cause mortality in the aetiological models, 
similar in magnitude to each other and stronger than eGFR. However, while they 
showed good discrimination, this was not significantly superior to eGFR. The models 
were well calibrated, but again, using the IDI, were not superior to eGFR. The strongest 
performer among the urinary markers was Urea-Cl.  
Iohexol plasma clearance performs well compared with inulin clearance, the historic 
gold standard GFR measure(13). It is considered to be more accurate than eGFR as it 
is closer to “true GFR”. Worsening kidney disease is associated strongly with increased 
all-cause mortality(1, 20). However eGFR equations were developed to estimate GFR, 
not for prognostication (though GFR itself is a strong predictor of prognosis). However it 
does not necessarily follow that iohexol mGFR is a superior predictor of all-cause 
mortality, as mGFR does not take account of non-GFR determinants of outcome such 
as protein-energy wasting, low muscle mass and reduced creatinine generation. In a 
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post-hoc analysis of the MDRD study, Tangri et al demonstrated that, after adjusting for 
GFR in their multi-variate model, a higher creatinine remained independently 
associated with lower mortality, demonstrating the role of the non-GFR determinants of 
creatinine(21). Conversely, low spot urine creatinine concentration is independently 
associated with mortality(22). Other work demonstrated an association between 
creatinine and non-traditional cardiovascular risk factors, independent of GFR(23). 
However in this study we have demonstrated the superior performance of mGFR over 
eGFR in the aetiological Cox models. A previous SRR-CKD study showed that the 
CKD-EPIcreat formulae overestimate GFR in advanced kidney disease(4). Our findings 
suggest that the superior accuracy of mGFR (and the independent relationship between 
GFR and all-cause mortality) outweighs the aetiological effects of the non-GFR 
determinants of outcome as measured by creatinine.  
The lack of superiority shown for formal urinary measures over eGFR (especially Creat-
Cl and Urea-Creat-Cl) may be because these measures reflect the same creatinine 
based non-GFR determinants of outcome as eGFR, or simply due to inaccuracies in the 
urine collections. Urea-Cl performed well to predict all-cause mortality. While it is 
inferior for measuring GFR alone (40-50% of filtered urea may be reabsorbed in the 
tubules), higher urea generation may reflect high protein content in the diet(3). 
Therefore this may be a marker of good patient outcome. The lack of a significant 
difference in discrimination and IDI for urinary measures over eGFR may simply reflect 
lack of statistical power (though discrimination models were consistent between the 
Creat-Cl group [n=1076] and the Urea-Creat-Cl group [n=527]). 
Calculating eGFR from a blood sample is undoubtedly the most convenient GFR 
assessment for patient, clinician and laboratory, not to mention cost effectiveness, and 
must be advocated for widespread use to identify those with CKD(24). Since eGFR 
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reporting was introduced, timed urine collection use has fallen dramatically in many 
countries, although is still advocated by some for patients with advanced CKD(25). 
However clinical practice differs between countries and we have exploited the ongoing 
practice of formal measures in Sweden for this study. In advanced CKD, where 
accurate measures of GFR will aid decision-making regarding timing of RRT, vascular 
access formation, or drug dosing, and the eGFR formulae are least accurate, clear 
benefits of a formal measure of GFR are seen. We have demonstrated the strong 
aetiological relationship with mortality which may aid prognostication in patients with 
advanced CKD. 
The strengths of this study lie in the inclusive, representative nature of the cohort, the 
large numbers undergoing mGFR testing and the complete follow-up of patients using 
linked national Swedish Registries. However, there are also limitations. As the study 
utilises routinely collected data, participants had the formal measure of GFR of their 
nephrologist’s choice, which could introduce confounding by indication. Only a sub-set 
had multiple contemporaneous measures, limiting direct comparisons. While data 
regarding date of death were complete, data regarding the cause of death were not 
which limited the analyses to all-cause mortality only. Ethnicity data were not recorded 
due to Swedish regulations. However the proportion of people from minority ethnic 
groups is low in Sweden and the findings will reflect the majority white population. 
These findings therefore may not translate to other ethnic groups. Data regarding 
smoking status and albuminuria were incomplete so these variables could not be 
included in the models. We did not have additional endogenous measures of kidney 
function such as cystatin C or beta trace protein to compare with the exogenous 
measures. Lastly iohexol mGFR is itself only an estimate of true GFR (which cannot be 
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directly measured) and we used only a single time-point so we were unable to 
investigate the influence of GFR slope on outcomes, as has been done elsewhere(26). 
These findings should be confirmed in a prospective cohort to exclude residual 
confounding or selection bias. Obtaining urinary measures, endogenous measures of 
eGFR and mGFR contemporaneously would allow direct comparisons. 
In conclusion, in aetiological and prognostic models, mGFR was superior to eGFR in 
predicting mortality in adults with CKD stage 4/5 attending Swedish nephrology clinics. 
This demonstrates the strong etiological role of GFR to predict adverse outcome versus 
the additional non-GFR determinants of outcome associated with creatinine-based 
eGFR. The relatively modest predictive enhancement suggests that eGFR may be 
sufficient to use in most scenarios in everyday clinical practice, while mGFR adds 
prognostic information when eGFR is believed or suspected to be biased.   
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Tables 
Table 1 Baseline demographics for a cohort of 2705 patients with multiple 
contemporaneous measurements of kidney function. 
  
Variable Total 
cohort 
n=2705 
Missing 
data for 
total 
cohort  
Iohexol 
sub-
group 
n=1517 
Urinary 
clearance  
sub-
group 
n=1194 
Difference 
between 
sub-
groups 
Age (years) 70  
(60 - 79) 
(range 
18-99) 
0% 72  
(61 - 79) 
69  
(59 - 78) 
p=0.001 
Gender (% male) 
 
66%  
 
0% 65% 69% p=0.041 
Primary Renal Disease 
Primary glomerulonephritis 
Interstitial disease 
Hypertension/renovascular 
Diabetic nephropathy 
Other 
CKD; aetiology unknown 
 
10.8% 
9.3% 
24.1% 
23.9% 
10.9% 
21.0% 
 
0%  
 
6.9% 
8.0% 
24.7% 
22.5% 
11.5% 
26.4% 
 
15.7% 
11.0% 
23.3% 
25.5% 
10.2% 
14.3% 
 
p<0.001 
Centre 
Local Hospital 
Regional Hospital 
University Hospital 
 
19.0% 
19.0% 
62.1% 
 
0% 
 
26.9% 
24.1% 
49.0% 
 
8.8% 
12.4% 
78.8% 
 
p<0.001 
Diabetes mellitus  36.8% 
 
0.6% 
 
36.9% 36.7% 0.732 
Antihypertensive 
medication* (number) 
3 (2 – 4) 0% 3 (2 – 4) 3 (2 – 4) p=0.004 
Protein restricted diet  
 
9% 0% 8.7% 9.4% p=0.513 
Weight (kg) 79.8 
(±17.4) 
 
2.2% 79.8 
(±17.7) 
79.8  
(±17.0) 
p=0.498 
Height (m)  1.71 
(±0.1) 
 
7.4% 1.70 
(±0.1) 
1.72  
(±0.1) 
p=0.001 
Body mass index (kg/m2) 
 
27.3 
(±5.5) 
7.9% 27.5 
(±5.7) 
27.0  
(±5.0) 
p=0.044 
Body Surface Area (m2) 1.91 
(±0.23) 
 
7.9% 1.91 
(±0.22) 
1.92  
(±0.23) 
p=0.172 
Mean arterial blood 
pressure (mmHg) 
99 (±14) 
 
2.9% 98 (±13) 100 (±14) p<0.001 
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Presented as median (interquartile range) or mean (±SD) unless otherwise stated. Data 
presented are for complete dataset, pre-imputation. Difference between groups was 
assessed using independent samples t test, Mann-Whitney U test or chi-square test as 
appropriate.  
*Antihypertensive medication includes diuretics 
  
Pulse pressure (mmHg) 
 
64 (±20) 
 
2.9% 
 
63 (±19) 65 (±20) p=0.058 
Weighted Charlson score 
 
3 (2 – 4) 0% 3 (2 – 4) 3 (2 – 4) p=0.103 
Serum creatinine  
(mg/dL) 
 
 
(mol/L) 
 
 
2.8  
(2.3 – 3.8) 
251  
(204–340) 
 
 
0% 
 
2.8  
(2.3 – 3.7) 
250  
(196–330) 
 
 
2.9  
(2.4 – 4.0) 
253  
(210–354) 
 
p=0.528 
eGFR (mL/min/1.73m2) 
(CKD-EPI) 
 
 20 
(14 – 26) 
0% 20  
(14 – 27) 
20  
(13 – 26) 
p=0.830 
mGFR (mL/min/1.73m2) 
 
- 0% of 
mGFR 
group 
18  
(13 – 23) 
 
- - 
24-hour creatinine 
clearance 
- 94% of 
urine cl 
group 
-  23  
(15 - 31) 
  
-  
24-hour urea clearance 
 
- 
 
46% of 
urine cl 
group 
-  14 (9 – 19) - 
24-hour urea-creatinine 
clearance 
- 56% of 
urine cl 
group 
- 18  
(12 – 24) 
- 
24-hour urine albumin  
(mg/day) 
532  
(119-
1896) 
20.7% 
 
667  
(106–
2396) 
523  
(119–
1753) 
p=0.891 
Albumin: creatinine ratio 
(mg/mmol) 
37  
(7 – 154) 
80.9% 30  
(5 – 127) 
59  
(11 – 206) 
p=0.011 
Haemoglobin (g/L) 
 
121 (±15) 
 
3.0% 
 
121 (±15) 121 (±15) p=0.382 
Albumin (g/L) 
 
36 (±4) 
 
3.5% 
 
36 (±4) 37 (±4) p=0.006 
Phosphate (mmol/L) 1.37 
(±0.35) 
5.6% 1.36 
(±0.35) 
 
1.37  
(±0.36) 
p=0.273 
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Table 2 Cox Proportional Hazards Model for all cause mortality comparing mGFR 
(using iohexol plasma clearance) and eGFR CKD-EPI (creatinine) in 1517 patients with 
contemporaneous measures.  
mGFR; measured Glomerular Filtration Rate, eGFR; estimated Glomerular Filtration Rate, 1SD; 1 standard deviation 
*Model 1 co-variates; age, sex; #Model 2 co-variates; age, sex, Charlson Score, 
Primary Renal Diagnosis, BMI, serum albumin; §Model 3 co-variates; age, sex, pulse 
pressure, Charlson Score, Primary Renal Diagnosis, BMI, serum albumin, 
Haemoglobin, commencement of RRT (modelled as a time-varying covariate) 
For each measure of kidney function (the predictor), the unadjusted hazard ratio is 
shown, followed by 3 models with co-variates, as described above (95% confidence 
intervals in brackets). The predictor variables were not normally distributed, therefore 
they were converted to a logarithmic scale. Then, in order to facilitate direct comparison 
the predictor variables were standardized (mean of zero and standard deviation of 1). In 
summary, the hazard ratios are described for the crude measure of the predictor and 
then per 1SD rise on a logarithmic scale. 
  
n=1517 Univariate Multivariate 
Model 1* 
Multivariate 
Model 2# 
Multivariate 
Model 3§ 
mGFR 
(ml/min/1.73m2) 
0.925  
(0.910 – 0.940) 
p<0.001 
0.930  
(0.914 – 0.945) 
p<0.001 
0.932  
(0.917 – 0.948) 
p<0.001 
0.947  
(0.930 – 0.964) 
p<0.001 
eGFR  
(ml/min/1.73m2) 
0.966 
(0.955 – 0.977) 
p<0.001 
0.965 
(0.954 – 0.977) 
p<0.001 
0.965 
(0.954 – 0.977) 
p<0.001 
0.983 
(0.970 – 0.996) 
p=0.009 
Standardised values on a logarithmic scale 
Log mGFR  
(per 1 SD) 
0.607 
(0.551 – 0.669) 
p<0.001 
0.624 
(0.564 – 0.690) 
p<0.001 
0.638 
(0.577 – 0.706) 
p<0.001 
0.709 
(0.633 – 0.793) 
p<0.001 
Log eGFR 
 (per 1 SD) 
0.783 
(0.716 – 0.855) 
p<0.001 
0.776 
(0.709 – 0.849) 
p<0.001 
0.778 
(0.710 – 0.853) 
p<0.001 
0.913 
(0.821 – 1.016) 
p=0.095 
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Table 3 Cox Proportional Hazards Model for all cause mortality comparing 24-h 
creatinine clearance, corrected for body surface area (BSA) of 1.73m2 and eGFR CKD-
EPI (creatinine) (also corrected for BSA) in 1076 patients with contemporaneous 
measures.  
eGFR; estimated Glomerular Filtration Rate, Creat; creatinine, 1SD; 1 standard deviation 
*Model 1 co-variates; age, sex; #Model 2 co-variates; age, sex, Charlson Score, 
Primary Renal Diagnosis, BMI, serum albumin; §Model 3 co-variates; age, sex, pulse 
pressure, Charlson Score, Primary Renal Diagnosis, BMI, serum albumin, 
Haemoglobin, commencement of RRT (modelled as a time-varying covariate) 
For each measure of kidney function (the predictor), the unadjusted hazard ratio is 
shown, followed by 3 models with co-variates, as described above (95% confidence 
intervals in brackets). The predictor variables were not normally distributed, therefore 
they were converted to a logarithmic scale. Then, in order to facilitate direct comparison 
the predictor variables were standardized (mean of zero and standard deviation of 1). In 
summary, the hazard ratios are described for the crude measure of the predictor 
(corrected for body surface area) and then per 1SD rise on a logarithmic scale. 
  
n=1076 Univariate Multivariate 
Model 1* 
Multivariate 
Model 2# 
Multivariate 
Model 3§ 
Creat 
Clearance 
(ml/min/1.73m2) 
0.956 
(0.946 – 
0.966) 
p<0.001 
0.964 
(0.953 – 0.974) 
p<0.001 
0.966  
(0.956 – 0.977) 
p<0.001 
0.978  
(0.966 – 
0.990) 
p<0.001 
eGFR 
(ml/min/1.73m2) 
0.965 
(0.954 – 
0.977) 
p<0.001 
0.967 
(0.955 – 0.979) 
p<0.001 
0.965 
(0.953 – 0.977) 
p<0.001 
0.983 
(0.969 – 
0.990.998) 
p=0.025 
Standardised values on logarithmic scale (using values corrected for BSA) 
Log Creat 
Clearance 
(per 1 SD) 
0.648 
(0.593 – 
0.708) 
p<0.001 
0.687 
(0.627 – 0.754) 
p<0.001 
0.705 
(0.642 – 0.774) 
p<0.001 
0.777 
(0.698 – 
0.863) 
p<0.001 
Log eGFR 
(per 1 SD) 
0.784 
(0.721 – 
0.854) 
p<0.001 
0.786 
(0.718 – 0.860) 
p<0.001 
0.779 
(0.710 – 0.854) 
p<0.001 
0.907 
(0.812 – 
1.013) 
p=0.084 
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Table 4 Sensitivity analysis of Cox Proportional Hazards Model for all cause mortality 
comparing 24-h urea-creatinine clearance, 24-h urea clearance, 24-h creatinine 
clearance corrected for body surface area (BSA) of 1.73m2, and eGFR CKD-EPIcreat 
(already corrected for BSA) in 527 patients with contemporaneous measures.  
95%CI; 95% confidence interval, eGFR; estimated Glomerular Filtration Rate, Creat; creatinine, 1SD; 1 standard deviation  
*Model 1 co-variates; age, sex; #Model 2 co-variates; age, sex, Charlson Score, 
Primary Renal Diagnosis, BMI, serum albumin; §Model 3 co-variates; age, sex, pulse 
pressure, Charlson Score, Primary Renal Diagnosis, BMI, serum albumin, 
Haemoglobin, commencement of RRT (modelled as a time-varying covariate) 
n=527 Univariate Multivariate 
Model 1* 
Multivariate 
Model 2# 
Multivariate 
Model 3§ 
Urea-Creat 
Clearance 
(ml/min/1.73m2) 
0.943 
(0.926 – 0.961) 
p<0.001 
0.957 
(0.939 – 0.976) 
p<0.001 
0.959 
(0.941 – 
0.978) 
P<0.001 
0.970  
(0.948 – 0.992) 
P=0.007 
Urea Clearance 
(ml/min/1.73m2) 
 
0.920 
(0.898 – 0.942) 
p<0.001 
0.938 
(0.915 – 0.963) 
p<0.001 
0.941 
(0.917 – 
0.965) 
p<0.001 
0.951 
(0.925 – 0.978) 
p<0.001 
Creat 
Clearance 
(ml/min/1.73m2) 
 
0.962 
(0.949 – 0.975) 
p<0.001 
 
0.972* 
(0.958 – 0.987) 
p<0.001 
 
0.974 
(0.959 – 
0.988) 
p<0.001 
 
0.984 
(0.967 – 
0.991.001) 
p=0.058 
eGFR CKD-EPI 
(ml/min/1.73m2) 
0.972 
(0.957 – 0.986) 
p<0.001 
0.975 
(0.960 – 0.991) 
p<0.001 
0.974 
(0.959 – 
0.990) 
p=0.002 
0.991 
(0.971 – 1.011) 
p=0.379 
Standardised values on logarithmic scale 
Log Urea-Creat 
Clearance  
(per 1 SD) 
0.640 
(0.567 – 0.723) 
p<0.001 
0.693 
(0.608 – 0.790) 
p<0.001 
0.711 
(0.624 – 
0.810) 
p<0.001 
0.757 
(0.648 – 0.884) 
p<0.001 
Log Urea 
Clearance  
(per 1 SD) 
0.617 
(0.543 – 0.700) 
p<0.001 
0.680 
(0.593 - 0.780) 
p<0.001 
0.693 
(0.603 – 
0.796) 
p<0.001 
0.737 
(0.631 – 0.860) 
p<0.001 
Log Creat 
Clearance  
(per 1SD)  
 
0.678 
(0.604 – 0.761) 
p<0.001 
0.724 
(0.641 – 0.818) 
p<0.001 
0.742 
(0.656 – 
0.838) 
p<0.001 
0.792 
(0.684 – 0.919) 
p=0.002 
Log eGFR 
CKD-EPI (per 1 
SD) 
0.827 
(0.744 – 0.920) 
p<0.001 
0.843 
(0.752 – 0.945) 
p<0.001 
0.841 
(0.749 – 
0.944) 
p=0.003 
0.969 
(0.833 – 1.128) 
p=0.687 
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For each measure of kidney function (the predictor), the unadjusted hazard ratio is 
shown, followed by 3 models with co-variates, as described above. The predictor 
variables were not normally distributed, therefore they were converted to a logarithmic 
scale. Then, in order to facilitate direct comparison the predictor variables were 
standardized (mean of zero and standard deviation of 1). In summary, the hazard ratios 
are described for the crude measure of the predictor and then per 1SD rise on a 
logarithmic scale. 
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Figures 
Figure 1 Flowchart of population and exclusions 
 
mGFR; measured Glomerular Filtration Rate, eGFR; estimated Glomerular Filtration Rate, sCr; serum creatinine, Creat Cl; 
creatinine clearance, Urea-Creat Cl; urea-creatinine clearance, Urea Cl; urea clearance 
 
  
Further exclusions 
• Duplicates n=179 
• <18 years old n=0 
• Missing sCr result n=10 
• Iohexol mGFR outliers n=24 
• Missing comorbidity data n=16 
Swedish CKD Register n= 13570 
Nephrology clinic visit with iohexol mGFR  
or urinary clearance measure n= 2968 
Exclude eGFR>45ml/min/1.73m2  
(according to mGFR AND eGFR) n=34 
Cases analysed n=2705 
Iohexol mGFR n=1517 
• Commenced RRT n=581 (38.3%) 
• Died n=471 (31%) 
• Median time to death – 23 months (IQR 12-37) 
• Died without starting RRT n=261 (ESKD n=41) 
• Died after starting RRT n=169 
Urinary clearance measures n=1188 
• Commenced RRT n=506 (42.6%) 
• Died n=497 (41.8%) 
• Median time to death – 23 months (IQR 10-42) 
• Died without starting RRT n=319 (ESKD n=34) 
• Died after starting RRT n=178 
Creat-Cl  
n=1076 
Urea-Creat-Cl  
n=527 
Urea-Cl 
 n=645 
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Figure 2 Kaplan Meier survival plots comparing (a) mGFR versus eGFR and (b) 
creatinine clearance versus eGFR. Patients were divided into tertiles according to 
kidney function defined by each test  
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Figure 2b 
 
mGFR; measured Glomerular Filtration Rate, eGFR; estimated Glomerular Filtration Rate, Creat Cl; creatinine clearance 
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Figure 3 Forest plots of unadjusted hazard ratios for all cause mortality comparing (a) 
mGFR and eGFR, in 1517 patients with contemporaneous measures (b) 24-h creatinine 
clearance (ml/min/1.73m2) and eGFR in 1076 patients with contemporaneous 
measures and (c) 24-h urea-creatinine clearance, 24-h urea clearance, 24-h creatinine 
clearance (all ml/min/1.73m2) and eGFR in 527 patients with contemporaneous 
measures 
 
Please note the sub-groups contain different individuals and hazard ratios can only be compared within the sub-group not across 
sub-groups ie comparison of mGFR with urea clearance is not valid 
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Figure 4 Discrimination models for 2 year all cause mortality comparing (a) mGFR 
(iohexol plasma clearance) with eGFR (CKD-EPI), (b) 24-h creatinine clearance with 
eGFR (CKD-EPI) and (c) 24-h urea-creatinine clearance with eGFR (CKD-EPI) 
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Figure 4b 
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Figure 4c 
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